The Potential of Induced Pluripotent Stem Cells to Advance the Treatment of Pancreatic Ductal Adenocarcinoma

Cancers

Noel F. C. C. de Miranda¹  Alexander L. Vahrmeijer²  Nigel G. Kooreman²  Ricki T. Krog² 

[1] Department of Pathology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands;Department of Surgery, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands;

关键词: pancreatic ductal adenocarcinoma;    PDAC;    induced pluripotent stem cells;    iPSCs;    cancer models;    cancer vaccine;   

DOI  :  10.3390/cancers13225789

来源: DOAJ

【 摘 要 】

Advances in the treatment of pancreatic ductal adenocarcinoma (PDAC) using neoadjuvant chemoradiotherapy, chemotherapy, and immunotherapy have had minimal impact on the overall survival of patients. A general lack of immunogenic features and a complex tumor microenvironment (TME) are likely culprits for therapy refractoriness in PDAC. Induced pluripotent stem cells (iPSCs) should be explored as a means to advance the treatment options for PDAC, by providing representative in vitro models of pancreatic cancer development. In addition, iPSCs could be used for tailor-made cellular immunotherapies or as a source of tumor-associated antigens in the context of vaccination.

【 授权许可】

Unknown